DK1313485T3 - Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion - Google Patents

Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Info

Publication number
DK1313485T3
DK1313485T3 DK01964471T DK01964471T DK1313485T3 DK 1313485 T3 DK1313485 T3 DK 1313485T3 DK 01964471 T DK01964471 T DK 01964471T DK 01964471 T DK01964471 T DK 01964471T DK 1313485 T3 DK1313485 T3 DK 1313485T3
Authority
DK
Denmark
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Application number
DK01964471T
Other languages
English (en)
Inventor
Kenton N Fedde
Alfonzo T Perez
Joseph F Tooley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1313485T3 publication Critical patent/DK1313485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DK01964471T 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion DK1313485T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28

Publications (1)

Publication Number Publication Date
DK1313485T3 true DK1313485T3 (da) 2005-12-27

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01964471T DK1313485T3 (da) 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (da)
EP (1) EP1313485B1 (da)
JP (1) JP2004507495A (da)
AT (1) ATE306272T1 (da)
AU (1) AU2001285318A1 (da)
CA (1) CA2419256A1 (da)
DE (1) DE60114027T2 (da)
DK (1) DK1313485T3 (da)
ES (1) ES2251505T3 (da)
WO (1) WO2002017895A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453495A2 (en) * 2001-11-23 2004-09-08 Akzo Nobel N.V. Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
PL372055A1 (en) * 2002-04-26 2005-07-11 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
WO2004060400A1 (ja) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp 上皮成長因子受容体を分子標的とする抗精神病薬
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US8933113B2 (en) 2011-01-20 2015-01-13 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9193717B2 (en) 2011-10-13 2015-11-24 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
ES2592818T3 (es) 2011-10-13 2016-12-01 Merck Sharp & Dohme Corp. Antagonistas del receptor de mineralocorticoides
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
KR100523409B1 (ko) * 1996-12-11 2005-10-24 지.디. 썰 엘엘씨 9,11-에폭시 스테로이드의 제조방법 및 이 제조방법에유용한 중간체
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JP2002529405A (ja) * 1998-11-06 2002-09-10 ジー・ディー・サール・アンド・カンパニー 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ATE249242T1 (de) * 1999-03-05 2003-09-15 Searle Llc Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Also Published As

Publication number Publication date
ATE306272T1 (de) 2005-10-15
DE60114027D1 (de) 2006-02-23
AU2001285318A1 (en) 2002-03-13
CA2419256A1 (en) 2002-03-07
US20060058274A1 (en) 2006-03-16
DE60114027T2 (de) 2006-07-13
JP2004507495A (ja) 2004-03-11
EP1313485A2 (en) 2003-05-28
US20020111337A1 (en) 2002-08-15
WO2002017895A3 (en) 2003-02-06
EP1313485B1 (en) 2005-10-12
ES2251505T3 (es) 2006-05-01
WO2002017895A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
MY143366A (en) Muscarinic acetylcholine receptor antagonists
AU3652102A (en) Compounds and their uses
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ECSP056254A (es) Antagonistas de receptores muscarínicos de la acetilcolina
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
MA27901A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
MXPA06000664A (es) Antagonistas del receptor muscarinico de acetilcolina.
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
DK1146872T3 (da) Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора